Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Entrada reports positive data from Phase 1 DMD trial

Entrada Therapeutics (NASDAQ:TRDA) has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular...

June 24, 2024

Developments

SOPHiA GENETICS expands oncology portfolio with new RAM application

SOPHiA GENETICS (NASDAQ:SOPH) has announced its new residual acute myeloid (RAM) application, SOPHiA DDM RAM Solution, supporting measurable residual disease (MRD) testing to help monitor cancer and outpace relapse. The...

June 24, 2024

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

OneMedNet forges alliance with clinical trial design and software global leader

OneMedNet (NASDAQ:ONMD) announced that it has entered into a significant iRWD customer data licensing agreement, partnering with an undisclosed U.S.-based global leader in clinical trial design and software with...

June 14, 2024

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...

June 13, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Executive Moves

Cantargia names Ton Berkien as CBO

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) announced the recruitment of Ton Berkien as Chief Business Officer effective October 1. Mr. Berkien joins the management team at Cantargia with approximately 30 years of...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

OneMedNet (NASDAQ:ONMD) announced that it has joined the Amazon Web Services (AWS) Partner Network (APN), significantly expanding industry access to its proprietary iRWD platform and securing an undisclosed...

June 6, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Entrada reports positive data from Phase 1 DMD trial

SOPHiA GENETICS expands oncology portfolio with new RAM application

BioRestorative Therapies gains media attention for key regenerative medicine programs

OneMedNet forges alliance with clinical trial design and software global leader

Former Hepion CEO sues over departure; cites bad faith dealings with investor

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Cantargia names Ton Berkien as CBO

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

OneMedNet joins AWS partner network as it enters into a “stage of anticipated rapid growth”

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

General

More